231 related articles for article (PubMed ID: 34225744)
1. Amplified antitumor efficacy by a targeted drug retention and chemosensitization strategy-based "combo" nanoagent together with PD-L1 blockade in reversing multidrug resistance.
Jiang W; Su L; Ao M; Guo X; Cheng C; Luo Y; Xie Z; Wang X; Wang J; Liu S; Cao Y; Li P; Wang Z; Ran H; Zhou Z; Ren J
J Nanobiotechnology; 2021 Jul; 19(1):200. PubMed ID: 34225744
[TBL] [Abstract][Full Text] [Related]
2. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
3. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
4. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
5. Dual-functionalized liposome by co-delivery of paclitaxel with sorafenib for synergistic antitumor efficacy and reversion of multidrug resistance.
Lei M; Ma G; Sha S; Wang X; Feng H; Zhu Y; Du X
Drug Deliv; 2019 Dec; 26(1):262-272. PubMed ID: 30856352
[TBL] [Abstract][Full Text] [Related]
6. Near-infrared light switching nitric oxide nanoemitter for triple-combination therapy of multidrug resistant cancer.
Wei G; Yang G; Wei B; Wang Y; Zhou S
Acta Biomater; 2019 Dec; 100():365-377. PubMed ID: 31586724
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of multifunctional paclitaxel-loaded polymeric mixed micelles as a potential anticancer remedy to overcome multidrug resistance.
Zhang J; Zhao X; Chen Q; Yin X; Xin X; Li K; Qiao M; Hu H; Chen D; Zhao X
Acta Biomater; 2017 Mar; 50():381-395. PubMed ID: 27956367
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
10. Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Ma Z; Li N; Zhang B; Hui Y; Zhang Y; Lu P; Pi J; Liu Z
J Nanobiotechnology; 2020 Sep; 18(1):123. PubMed ID: 32887626
[TBL] [Abstract][Full Text] [Related]
11. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
[TBL] [Abstract][Full Text] [Related]
12. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z
Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433
[TBL] [Abstract][Full Text] [Related]
13. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
14. Computer-assisted engineering of programmed drug releasing multilayer nanomedicine via indomethacin-mediated ternary complex for therapy against a multidrug resistant tumor.
Che L; Liu Z; Wang D; Xu C; Zhang C; Meng J; Zheng J; Yuan H; Zhao G; Zhou X
Acta Biomater; 2019 Oct; 97():461-473. PubMed ID: 31344512
[TBL] [Abstract][Full Text] [Related]
15. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
[TBL] [Abstract][Full Text] [Related]
16. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity.
Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X
Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920
[TBL] [Abstract][Full Text] [Related]
17. TPGS and chondroitin sulfate dual-modified lipid-albumin nanosystem for targeted delivery of chemotherapeutic agent against multidrug-resistant cancer.
Luo K; Xu F; Yao T; Zhu J; Yu H; Wang G; Li J
Int J Biol Macromol; 2021 Jul; 183():1270-1282. PubMed ID: 34004196
[TBL] [Abstract][Full Text] [Related]
18. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
19. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
[TBL] [Abstract][Full Text] [Related]
20. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
